Serial Gadolinium-enhanced MRI in Relapsing/remitting Multiple Sclerosis of Varying Disease Duration

Overview

Journal Neurology

Specialty Neurology

Date 1992 Jan 1

PMID 1734325

Citations 28

Authors

A J Thompson

D Miller

B Youl

D MacManus

S Moore

D Kingsley

B Kendall

A Feinstein

W I McDonald

Affiliations

Soon will be listed here.

Abstract

In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.

Citing Articles

[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Aktas O, Wattjes M, Stangel M, Hartung H Nervenarzt. 2018; 89(12):1344-1354.

PMID: 29876600 DOI: 10.1007/s00115-018-0550-0.

Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2.

Brod S Pharmaceuticals (Basel). 2016; 3(4):1108-1121.

PMID: 27713291 PMC: 4034024. DOI: 10.3390/ph3041108.

Neuroradiological evaluation of demyelinating disease.

Tillema J, Pirko I Ther Adv Neurol Disord. 2013; 6(4):249-68.

PMID: 23858328 PMC: 3707351. DOI: 10.1177/1756285613478870.

Central inflammation versus peripheral regulation in multiple sclerosis.

Edwards L, Sharrack B, Ismail A, Tumani H, Constantinescu C J Neurol. 2011; 258(8):1518-27.

PMID: 21547381 DOI: 10.1007/s00415-011-5973-5.

Neutralizing antibodies against interferon-Beta.

Soelberg Sorensen P Ther Adv Neurol Disord. 2010; 1(2):125-41.

PMID: 21180570 PMC: 3002544. DOI: 10.1177/1756285608095144.